NasdaqGS:BCRX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines.


Snowflake Analysis

Mediocre balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has BioCryst Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BCRX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-7.3%

BCRX

1.6%

US Biotechs

1.1%

US Market


1 Year Return

78.7%

BCRX

23.8%

US Biotechs

4.6%

US Market

Return vs Industry: BCRX exceeded the US Biotechs industry which returned 23.8% over the past year.

Return vs Market: BCRX exceeded the US Market which returned 4.6% over the past year.


Shareholder returns

BCRXIndustryMarket
7 Day-7.3%1.6%1.1%
30 Day46.5%4.5%5.5%
90 Day89.4%11.0%-4.9%
1 Year78.7%78.7%25.0%23.8%7.0%4.6%
3 Year1.0%1.0%35.8%31.3%28.6%20.1%
5 Year-57.6%-57.6%-2.3%-8.2%52.5%35.3%

Price Volatility Vs. Market

How volatile is BioCryst Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioCryst Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BCRX ($5.2) is trading below our estimate of fair value ($15.36)

Significantly Below Fair Value: BCRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BCRX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: BCRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BCRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BCRX is overvalued based on its PB Ratio (219.8x) compared to the US Biotechs industry average (3.8x).


Next Steps

Future Growth

How is BioCryst Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

46.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BCRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BCRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BCRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BCRX's revenue (46.2% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: BCRX's revenue (46.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BCRX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has BioCryst Pharmaceuticals performed over the past 5 years?

-24.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BCRX is currently unprofitable.

Growing Profit Margin: BCRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BCRX is unprofitable, and losses have increased over the past 5 years at a rate of -24.1% per year.

Accelerating Growth: Unable to compare BCRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BCRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: BCRX has a negative Return on Equity (-3164.53%), as it is currently unprofitable.


Next Steps

Financial Health

How is BioCryst Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: BCRX's short term assets ($125.5M) exceed its short term liabilities ($92.7M).

Long Term Liabilities: BCRX's short term assets ($125.5M) exceed its long term liabilities ($40.2M).


Debt to Equity History and Analysis

Debt Level: BCRX's debt to equity ratio (2198.7%) is considered high.

Reducing Debt: BCRX's debt to equity ratio has increased from 46.4% to 2198.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BCRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BCRX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 24.9% each year


Next Steps

Dividend

What is BioCryst Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BCRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BCRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BCRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.6yrs

Average management tenure


CEO

Jon Stonehouse (58yo)

13.33yrs

Tenure

US$2,284,297

Compensation

Mr. Jon P. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co., Ltd. since joining in January 8, 2007 and also has been its President  ...


CEO Compensation Analysis

Compensation vs Market: Jon's total compensation ($USD2.28M) is about average for companies of similar size in the US market ($USD3.23M).

Compensation vs Earnings: Jon's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jon Stonehouse
CEO, President & Director13.33yrsUS$2.28m0.51% $4.1m
William Sheridan
Chief Medical Officer & Senior VP11.83yrsUS$1.07m0.0055% $44.0k
Yarlagadda Babu
Senior Vice President of Drug Discovery6.58yrsUS$1.08m0.10% $809.0k
Megan Sniecinski
Senior VP & Chief Business Officer0.83yrUS$2.18m0.029% $234.0k
Anthony Doyle
Senior VP & CFO0.083yrno datano data
Michael Jones
Executive Director of Finance & Principal Accounting Officer0.33yrno data0.00055% $4.4k
John Bluth
Senior Vice President of Investor Relations & Corporate Communicationsno datano datano data
Alane Barnes
Senior VP13.67yrsUS$1.33m0.066% $530.7k
Robert Stoner
Vice President of Human Resourcesno datano datano data
Elliott Berger
Senior Vice President of Regulatory Affairsno datano datano data

6.6yrs

Average Tenure

53yo

Average Age

Experienced Management: BCRX's management team is seasoned and experienced (6.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jon Stonehouse
CEO, President & Director13.33yrsUS$2.28m0.51% $4.1m
Stephen Aselage
Independent Director1.33yrsUS$280.19k0.016% $130.5k
Robert Ingram
Independent Chairman3yrsUS$154.09k0.039% $316.8k
Alan Levin
Independent Director0.25yrno datano data
Kenneth Lee
Independent Director8.92yrsUS$134.09k0.0099% $79.3k
George Abercrombie
Independent Director8.58yrsUS$129.71k0.0065% $52.0k
Helen Thackray
Independent Director0.67yrUS$95.30kno data
Theresa Heggie
Independent Director1.42yrsUS$119.71k0.0065% $52.5k
Nancy Hutson
Independent Director8.33yrsUS$134.09k0.039% $311.4k

3.0yrs

Average Tenure

64yo

Average Age

Experienced Board: BCRX's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.8%.


Top Shareholders

Company Information

BioCryst Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioCryst Pharmaceuticals, Inc.
  • Ticker: BCRX
  • Exchange: NasdaqGS
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$802.117m
  • Shares outstanding: 154.25m
  • Website: https://www.biocryst.com

Number of Employees


Location

  • BioCryst Pharmaceuticals, Inc.
  • 4505 Emperor Boulevard
  • Suite 200
  • Durham
  • North Carolina
  • 27703
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BCRXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 1994
BO1DB (Deutsche Boerse AG)YesCommon StockDEEURMar 1994
BCRX *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNMar 1994

Biography

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/27 11:57
End of Day Share Price2020/05/26 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.